<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04442984</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01</org_study_id>
    <nct_id>NCT04442984</nct_id>
  </id_info>
  <brief_title>FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)</brief_title>
  <acronym>IRIGA</acronym>
  <official_title>FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (Type II-III): Open-label Randomized Phase 2/3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with metastatic adenocarcinoma of the stomach or the esophagogastric junction
      (II-III type by Siewert) without previous therapy will be treated with one of two
      chemotherapy combinations . One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin,
      Oxaliplatin (FOLFOX6), the others 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and
      Irinotecan (mFOLFIRINOX). Main objective of the study is progression free survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This parallel, randomized, open-label study 326 patients with metastatic ( adenocarcinoma of
      the stomach or the esophagogastric junction without previous therapy will be included in this
      study. After randomization patients receive 9 cycles FOLFOX6 or mFOLFIRINOX.

      Stratification factors include ECOG, site of metastasis, age, pathological subtypes.

      Efficacy will be evaluated every 3 cycles with RECIST. Toxicity will be assessed with WHO CTC
      3.0 every 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2019</start_date>
  <completion_date type="Anticipated">November 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 3, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>36 months</time_frame>
    <description>PFS is defined as the time from the date of randomization to the date of the first documentation of progressive disease or date of death, whichever occurs first. For target lesions (TL), PD was defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD) of TLs, taking as a reference the smallest SLD recorded since the treatment started, or the appearance of one or more lesions. For non-target lesions (NTL), PD was defined as an unequivocal progression of existing NTLs. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>60 months</time_frame>
    <description>OS is defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log or the date of last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment associated toxicities</measure>
    <time_frame>12 months</time_frame>
    <description>WHO CTC 3.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">326</enrollment>
  <condition>Gastric Carcinoma Stage IV</condition>
  <condition>Esophagogastric Junction Adenocarcinoma Stage IV</condition>
  <arm_group>
    <arm_group_label>FOLFOX6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5FU 400mg/m2 iv bolus d1, 5-FU 2400 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 180mg/m2 d1, 5FU 250mg/m2 iv bolus d1, 5-FU 2200 mg/m² d1-2, Leucovorin 400 mg d1, Oxaliplatin 85 mg/m² d1, every two weeks (q2w) 9 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>d1 Irinotecan 180mg/m² every two weeks</description>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>d1 Oxaliplatin 85 mg/m² every two weeks</description>
    <arm_group_label>FOLFOX6</arm_group_label>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>d1-2 5-FU 2200 mg/m² every two weeks</description>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>d1 5-FU 250 mg/m² every two weeks</description>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>d1 Leucovorin 400 mg every two weeks</description>
    <arm_group_label>FOLFOX6</arm_group_label>
    <arm_group_label>mFOLFIRINOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>d1 5-FU 400 mg/m² every two weeks</description>
    <arm_group_label>FOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>d1-2 5-FU 2400 mg/m² every two weeks</description>
    <arm_group_label>FOLFOX6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically confirmed locally advanced, recurrent or metastatic adenocarcinoma of
             the esophagogastric junction (Siewert type II-III) or the stomach

          2. no prior palliative chemotherapy or radiation therapy

          3. Age 18-70 years (female and male)

          4. Eastern Cooperative Oncology Group ≤ 2

          5. Neutrophils&gt; 2.000/µl

          6. Platelets &gt; 100.000/µl

          7. Normal value of Serum Creatinin

          8. Albumin level &gt; 29 г/л

          9. Aspartate transaminase (AST) or alanine transaminase (ALT) less than 3 times the upper
             limits of normal (ULN)

         10. Total Bilirubin less than 1.5 times the ULN

         11. Written informed consent.

        Exclusion Criteria:

          1. Previous palliative cytostatic chemotherapy

          2. Cancer relapse

          3. Complicated gastric cancer (perforation, bleeding, sub or decompensated stenosis,
             dysphagia IV)

          4. Diarrhea ≥ 2 according to the criteria of Common Terminology Criteria for Adverse
             Events (CTCAE) version 4.1;

          5. Hypersensitivity against 5- Fluorouracil, Leucovorin, Oxaliplatin, irinotecan

          6. Existence of contraindications against 5- Fluorouracil, Leucovorin, Oxaliplatin,
             Irinotecan or Docetaxel

          7. Active coronary heart disease, Cardiomyopathy or cardiac insufficiency stage III-IV
             according to New York Heart Association (NYHA)

          8. Severe non-surgical accompanying disease or acute infection (uncontrolled arterial
             hypertension, diabetes mellitus, stroke less than 6 months old, mental disorders,
             other tumors and others)

          9. Malignant secondary disease, dated back &lt; 5 years (exception: In-situ-carcinoma of the
             cervix uteri, adequately treated skin basal cell carcinoma)

         10. Peripheral polyneuropathy &gt; Grad II

         11. Liver dysfunction (AST)/ALT&gt;3,0xULN, ALT&gt;3xULN, Bilirubin&gt;1,5xULN) Serum Creatinin
             &gt;1,0xULN

         12. Chronic inflammable gastro-intestinal disease

         13. Inclusion in another clinical trial

         14. Pregnancy or lactation

         15. Hepatitis B or C in the active stage

         16. Human immunodeficiency virus(HIV) infected

         17. Serious concomitant somatic and mental illnesses / deviations or territorial causes
             that may prevent the patient from participating in the protocol and observing the
             protocol schedule

         18. Foreigners or persons with limited legal status
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tatiana Titova</last_name>
    <phone>+79152982811</phone>
    <email>tatiana.titovadoc@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blokhin's Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Titova</last_name>
      <phone>+79152982811</phone>
      <email>tatiana.titovadoc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Artamonova Elena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

